{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:33:36Z","timestamp":1773423216118,"version":"3.50.1"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Bruton's tyrosine kinase (BTK) is important in B\u2010cell signalling. Efficacy has been reported for BTK inhibitors (BTKi) in human autoimmune diseases. Canine pemphigus foliaceus (cPF) is the most common canine autoimmune skin disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine the safety and efficacy of a BTKi in cPF treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Animals<\/jats:title><jats:p>Nine privately owned dogs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and materials<\/jats:title><jats:p>Nine dogs diagnosed with PF were administered BTKi PRN473. Initial dosages were \u224815\u00a0mg\/kg once daily, increased to twice daily if inadequate response was seen. Treatment continued for a maximum of 20\u00a0weeks, attempting decrease to every other day. Dogs were monitored with complete blood counts, serum biochemistry panels, urinalyses and evaluated with a modified version of a validated human Pemphigus Disease Activity Index (cPDAI). Anti\u2010desmocollin\u20101 (DSC\u20101) and desmoglein\u20101 (DSG\u20101) immunoglobulin G (IgG) titres were performed before and after the treatment period. Drug bound to target was measured in peripheral blood mononuclear cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All nine dogs showed reduction in lesions and cPDAI score during the first two weeks of treatment. At the end of the study, four responses were considered \u201cgood\u201d, two \u201cfair\u201d, two \u201cpoor\u201d and one dog withdrawn due to recurrence of a previously excised mast cell tumour. Four dogs continued to improve by Week 4; three sustained near complete remission by study's end. The anti\u2010DSC\u20101 IgG titre decreased in three dogs, increased in two, was undetected in three and was not performed in the withdrawn dog. No dogs had detectable IgG to DSG1. Possible adverse effects occurred in three dogs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and clinical importance<\/jats:title><jats:p>Bruton's tyrosine kinase inhibitor monotherapy may have beneficial effects in some cases of cPF.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vde.12841","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T14:46:06Z","timestamp":1578062766000},"page":"291","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN\u2010473) in the treatment of canine pemphigus foliaceus"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9804-173X","authenticated-orcid":false,"given":"Elizabeth C.","family":"Goodale","sequence":"first","affiliation":[{"name":"Department of Medicine and Epidemiology School of Veterinary Medicine University of California One Shields Avenue Davis CA 95616 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina E.","family":"Varjonen","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology School of Veterinary Medicine University of California One Shields Avenue Davis CA 95616 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-4484","authenticated-orcid":false,"given":"Catherine A.","family":"Outerbridge","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology School of Veterinary Medicine University of California One Shields Avenue Davis CA 95616 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-0528","authenticated-orcid":false,"given":"Petra","family":"Bizikova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology and Immunology School of Veterinary Medicine University of California One Shields Avenue Davis CA 95616 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dori","family":"Borjesson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences College of Veterinary Medicine NC State University 1060 William Moore Drive Raleigh NC 27607 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-0199","authenticated-orcid":false,"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[{"name":"Department of Dermatology St George Hospital University of New South Wales Sydney New South Wales 2052 Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Bisconte","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc. 400 E Jamie Ct South San Francisco CA 94080 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Francesco","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc. 400 E Jamie Ct South San Francisco CA 94080 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Hill","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc. 400 E Jamie Ct South San Francisco CA 94080 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Masjedizadeh","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc. 400 E Jamie Ct South San Francisco CA 94080 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Nunn","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc. 400 E Jamie Ct South San Francisco CA 94080 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Gourlay","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc. 400 E Jamie Ct South San Francisco CA 94080 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3103-6930","authenticated-orcid":false,"given":"Stephen D.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology School of Veterinary Medicine University of California One Shields Avenue Davis CA 95616 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2004.224.1312"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2004.00360.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.5326\/0420189"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2012.06.025"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2005.10.002"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/9780470752487","volume-title":"Skin Diseases of the Dog and Cat, Clinical and Histopathologic Diagnosis","author":"Gross TL","year":"2005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12241"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2460\/javma.1991.199.01.77","article-title":"Diabetes mellitus induced in a dog after administration of corticosteroids and methylprednisolone pulse therapy","volume":"199","author":"Jeffers JG","year":"1991","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_6_10_1","first-page":"722","article-title":"Agammaglobulinemia. [First report describing humoral immunodeficiency in a male child with a disease later termed x\u2010linked agammablobulinemia (XLA) and attributed to Bruton's tyrosine kinase deficiency]","volume":"9","author":"Bruton OC","year":"1952","journal-title":"Pediatrics"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1152888"},{"key":"e_1_2_6_12_1","first-page":"67","article-title":"BTK signaling in B cell differentiation and autoimmunity","volume":"393","author":"Corneth OB","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1046"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397919"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.4.1850"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn413"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104441"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-018-0069-7"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2011.08073.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159607"},{"key":"e_1_2_6_23_1","unstructured":"MurrellDF StavroupoulosP PatsatsiAet al.Clinical endpoint analysis of the Believe\u2010PV phase 2 study of PRN1008 in pemphigus. Presented at Medical Dermatology Society\u2013 2018 Annual Meeting February 2018. Available at:https:\/\/www.principiabio.com\/wp-content\/uploads\/2019\/12\/2018.02-PRN1008-Murrell-MDS.pdfAccessed Feb 23 2020."},{"key":"e_1_2_6_24_1","unstructured":"MontalbanX.Primary analysis of a randomized placebo\u2010controlled phase 2 study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis (abstract). 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis October 2018. Available at:https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2018\/ectrims-2018\/232075\/xavier.montalban.primary.analysis.of.a.randomised.placebo-controlled.phase.2.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DevobrutiniAccessed Feb 23 2020."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0188-8"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1817"},{"issue":"1","key":"e_1_2_6_27_1","doi-asserted-by":"crossref","first-page":"139.6","DOI":"10.4049\/jimmunol.194.Supp.139.6","article-title":"Efficacy in collagen induced arthritis models with a selective, reversible covalent Bruton's tyrosine kinase inhibitor PRN473 is driven by durable target occupancy rather than extended plasma exposure (THER5P.904)","volume":"194","author":"Bisconte A","year":"2015","journal-title":"J Immunol"},{"key":"e_1_2_6_28_1","unstructured":"SmithPF KarrD BisconteAet al.Development of a disease model of Bruton's tyrosine kinase (BTK) inhibition by PRN473 in rat collagen\u2010induced arthritis (rCIA). Poster presented at American Conference on Pharmacometrics. Las Vegas NV USA: Oct 12\u201315 2014. Available at:https:\/\/www.go-acop.org\/assets\/Legacy_ACOPs\/ACOP5\/Poster_Abstracts\/w-049.pdfAccessed Feb 23 2020."},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14090"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.72"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.042"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.70.807"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01712"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.084459"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.040840"},{"key":"e_1_2_6_36_1","unstructured":"OuterbridgeC GoodaleE VarjonenKet al.A new treatment for autoimmune blistering diseases: efficacy of the Bruton's tyrosine kinase (BTK) inhibitor PRN473 in canine pemphigus foliaceus. Poster presented at American Academy of Dermatology Annual Meeting 2016.Washington DC USA: March 2016. Available athttps:\/\/www.principiabio.com\/technology\/presentations-publications\/page\/3\/Accessed Feb 23 2020."},{"key":"e_1_2_6_37_1","unstructured":"MurrellDF GourlayS FrancescoMet al.A pilot study of the efficacy of a Bruton's tyrosine kinase inhibitor in the treatment of dogs with pemphigus foliaceus 2019.Poster presented at The Australasian College of Dermatologists \u2013 2017 Annual Scientific Meeting May 2017. Available at:https:\/\/www.principiabio.com\/technology\/presentations-publications\/page\/2\/Accessed Feb 23 2020."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13351"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00306"},{"key":"e_1_2_6_40_1","first-page":"433","article-title":"Prevalence of comorbid immune\u2010mediated disease in dogs with pemphigus foliaceus: a retrospective study","volume":"28","author":"Falk EF","year":"2017","journal-title":"Vet Dermatol"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.338"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.11980"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12520"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3439"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.011"},{"key":"e_1_2_6_46_1","first-page":"291","article-title":"Detection of anti\u2010desmocollin\u20101 and anti\u2010desmoglein\u20101 autoantibodies in dogs with pemphigus foliaceus with or without the classic facial involvement","volume":"30","author":"Bizikova P","year":"2019","journal-title":"Vet Dermatol"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-008-9011-1"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvde.12841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.12841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vde.12841","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.12841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T17:42:29Z","timestamp":1722274949000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.12841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/vde.12841"],"URL":"https:\/\/doi.org\/10.1111\/vde.12841","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"2019-12-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}